Conflict of Interest Declaration
The following Task Force members and other authors declared an intellectual conflict of interest, and this was acknowledged and managed by the Task Force Chairs and Conflict of Interest Committee: None applicable
CoSTR Citation
Couper K, Gray J, Grunau B, Katzenschlager S, Drennan IR, Scholefield B, Lavonas EJ on behalf of the International Liaison Committee on Resuscitation Advanced Life Support Task Force and Pediatric Life Support Task Force. Non-opioid toxicological causes of cardiac arrest, Consensus on Science with Treatment Recommendations [Internet] Brussels, Belgium: International Liaison Committee on Resuscitation (ILCOR) Advanced Life Support Task Force and Pediatric Life Support Task Force, October 27, 2026.
Background
This was a new ILCOR systematic review (CRD420251149412). All evidence identified was considered by the Advanced Life Support and Pediatric Life Support Task Forces and is described below. Discussion points and highlights of the evidence-to-decision process are also included. All data were considered when formulating the Treatment Recommendations. Data tables and the evidence-to-decision framework are provided as attachments.
Review Citation
Couper K, Alenazi A, Gray J, Grunau B, Katzenschlager S, Rutherford B, Simpson MD, Drennan IR, Scholefield B, Lavonas EJ. Intra-arrest strategies to treat cardiac arrest due to non-opioid toxicological causes in adults and children: a systematic review. Resuscitation Plus 2026: 101501. doi:10.1016/j.resplu.2026.101501.
PICOST
The PICOST (Population, Intervention, Comparator, Outcome, Study Designs and Timeframe)
Population:
Adults and children in any setting (in-hospital or out-of-hospital) with cardiac arrest due to a presumed toxicological cause
Intervention:
Any specific alteration to standard Advanced Life Support during ongoing cardiopulmonary resuscitation
Comparator:
Either: Standard Advanced Life Support, OR, Any other specific alteration to standard Advanced Life Support during ongoing cardiopulmonary resuscitation
Outcomes:
Health-related quality of life at 3-months/ 6-months (or longest follow-up)- Critical
Survival with favourable neurological outcome at discharge/30-days; 3-months; 6-months (or longest follow-up)- Critical
Survival at discharge/30-days; 3-months; 6-months (or longest follow-up)- Critical
Sustained return of spontaneous circulation (at hospital handover or 20-minutes)- Important
Any return of spontaneous circulation- Important.
Survival to ICU discharge was included as a post hoc outcome and categorised as an important outcome as it is a time-point that occurs prior to hospital discharge.
Study Designs:
Randomized controlled trials (RCTs) and non-randomized studies with a control group (e.g. non-randomized controlled trials, interrupted time series, controlled before-and-after studies, cohort studies) in humans.
Unpublished studies (e.g., conference abstracts, trial protocols) and non-human studies (e.g. animal, simulation) are excluded.
Timeframe: All years and all languages are included as long as there is an English abstract
Registration: PROSPERO CRD420251149412
Consensus on Science
Our four eligible studies were all retrospective cohort studies which enrolled between 10 and 1545 participants.1-4 Two studies used data from single emergency medical services (EMS) systems,3,4 one study enrolled patients from across two hospitals,2 and the final study used data from an American Association of Poison Control Centers (AAPCC) accredited regional poison centre that covered three US states.1 Two studies examined specific toxicological causes of cardiac arrest: smoke inhalation with suspected cyanide poisoning;3 and beta-blockers or calcium-channel blockers.1 The remaining two studies included a range of toxicological causes of cardiac arrest.2,4 One study specifically included children, but these data could not be incorporated within the evidence synthesis due to the way in which they were reported.3
General toxicological causes of cardiac arrest
Sodium bicarbonate
For the critical outcome of survival to hospital discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias) from one observational study enrolling 1545 patients (568 received sodium bicarbonate),4 which showed a statistical association between use of sodium bicarbonate and lower survival to hospital discharge, compared with standard care (adjusted odds ratio 0.16, 95% confidence interval 0.08 to 0.31)
E-CPR
For the important outcome of survival to ICU discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias and very serious imprecision) from one observational study enrolling 10 patients (three received E-CPR),2 which showed a statistical association between use of E-CPR and higher survival to ICU discharge, compared with standard care (unadjusted odds ratio 105.00, 95% confidence interval 1.71 to 6465.65; absolute difference 129 more survivors per 1000, 95% confidence interval 1 more to 901 more).
Calcium channel blocker/ beta-blocker overdose
Fat emulsion
For the critical outcome of survival to hospital discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias, serious indirectness and very serious imprecision) from one observational study enrolling 41 patients (14 received fat emulsion),1 which showed no statistical association between use of fat emulsion and survival to hospital discharge, compared with standard care (unadjusted odds ratio 0.15, 95% confidence interval 0.02 to 1.37; absolute difference 264 fewer survivors per 1000, 95% confidence interval 323 fewer to 73 more).
Glucagon
For the critical outcome of survival to hospital discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias, serious indirectness and very serious imprecision) from one observational study enrolling 41 patients (nine received glucagon),1 which showed no statistical association between use of glucagon and survival to hospital discharge, compared with standard care (unadjusted odds ratio 0.32, 95% confidence interval 0.03 to 2.93; absolute difference 170 fewer survivors per 1000, 95% confidence interval 270 fewer to 253 more).
Methylene blue
For the critical outcome of survival to hospital discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias, serious indirectness and very serious imprecision) from one observational study enrolling 41 patients (four received methylene blue),1 which showed no statistical association between use of methylene blue and survival to hospital discharge, compared with standard care (unadjusted odds ratio 0.29, 95% confidence interval 0.01 to 5.89; absolute difference 173 fewer survivors per 1000, 95% confidence interval 267 fewer to 415 more).
Pacemaker
For the critical outcome of survival to hospital discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias, serious indirectness and very serious imprecision) from one observational study enrolling 41 patients (seven received a pacemaker),1 which showed no statistical association between use of a pacemaker and survival to hospital discharge, compared with standard care (unadjusted odds ratio 1.30, 95% confidence interval 0.21 to 8.03; absolute difference 50 more survivors per 1000, 95% confidence interval 175 fewer to 477 more).
Intra-aortic balloon pump
For the critical outcome of survival to hospital discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias, serious indirectness and very serious imprecision) from one observational study enrolling 41 patients (five received an intra-aortic balloon pump),1 which showed no statistical association between use of intra-aortic balloon pump and survival to hospital discharge, compared with standard care (unadjusted odds ratio 0.23, 95% confidence interval 0.01 to 4.53; absolute difference 197 fewer survivors per 1000, 95% confidence interval 274 fewer to 358 more).
ECMO
For the critical outcome of survival to hospital discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias, serious indirectness and very serious imprecision) from one observational study enrolling 41 patients (two received ECMO),1 which showed no statistical association between use of ECMO and survival to hospital discharge, compared with standard care (unadjusted odds ratio 0.56, 95% confidence interval 0.02 to 12.69; absolute difference 95 fewer survivors per 1000, 95% confidence interval 250 fewer to 558 more).
Smoke inhalation with suspected cyanide poisoning
Hydroxocobalamin
In the study of hydroxocobalamin, eight patients received higher dose hydroxocobalamin (>5g) and 45 received lower dose hydroxocobalamin (≤5g).3
For the critical outcome of survival to hospital discharge, we identified very low certainty evidence (downgraded for extremely serious risk of bias and serious imprecision) from one observational study enrolling 53 patients,3 which showed a statistical association between higher-dose (>5g) hydroxocobalamin and increased survival to hospital discharge, compared with lower-dose (≤5g) hydroxocobalamin (unadjusted odds ratio 12.90, 95% confidence interval 1.72 to 96.73; absolute difference 331 more survivors per 1000, 95% confidence interval 30 more to 774 more).
For the important outcome of ROSC, we identified very low certainty evidence (downgraded for extremely serious risk of bias and serious imprecision) from one observational study enrolling 53 patients,3 which showed a statistical association between use of higher-dose (>5g) hydroxocobalamin and ROSC, compared with lower-dose (≤5g) hydroxocobalamin (unadjusted odds ratio 19.37, 95% confidence interval 1.05 to 355.75; absolute difference 478 more survivors per 1000, 95% confidence interval 12 more to 530 more).
Treatment Recommendation or Good Practice Statement
For non-opioid toxicological causes of cardiac arrest, there is no reliable evidence to support the routine modification of Advanced Life Support in either adults or children (weak recommendation, very low certainty of evidence).
In cases where a toxicological cause is suspected, despite a lack of direct evidence, providers may consider use of specific antidotes provided this does not detract from the delivery of standard Advanced Life Support. (Taskforce Insight).
Justification and Evidence to Decision Framework Highlights
Evidence limitations
This CoSTR combines and updates a range of previous ILCOR treatment recommendations focused on specific toxins, with the exception of opioid toxicity.
The task forces noted that the four available studies evaluated different interventions across several presumed toxicological causes of cardiac arrest. All studies were observational and were judged to be at critical risk of bias, resulting in very low certainty evidence. Observational studies evaluating interventions during toxicological cardiac arrest are particularly susceptible to confounding by indication, as patients receiving rescue therapies are often those with the most severe poisoning or greatest physiological derangement. Consequently, observed associations between an intervention and outcome cannot be assumed to represent a causal effect.
The task forces noted that undertaking research in this area is extremely challenging, which is likely reflected by the low number of identified studies. The absence of comparative studies meeting the inclusion criteria for specific toxins or interventions should not necessarily be implied as evidence that these interventions are ineffective.
In determining the eligibility criteria for this CoSTR and associated systematic review, the task forces carefully considered the inclusion of studies without a control group (e.g. case series/ case reports) and animal studies. In deciding to exclude case series and case reports, the task forces were cognisant of the inherent risk of selection bias and publication bias associated with such studies. In deciding to exclude animal studies, the task forces were cognisant of the challenges in translating findings from animal models of cardiac arrest to cardiac arrest in humans.5,6
The systematic review identified one study including eight children, but given the way in which these data were reported, it was not possible to include them within the evidence synthesis. The application of the available evidence to pediatric cardiac arrest is indirect.
Clinical and biological heterogeneity
The mechanisms by which toxins cause cardiac arrest vary. Some toxins may have a primary cardiac effect, while others may cause hypoxemia, vasoplegia, metabolic disturbance, or a combination of mechanisms. The potential reversibility of toxin-related cardiac arrest, and the likelihood that a specific intervention will be effective, is uncertain and may vary according to the toxin and the mechanism of arrest.
Identification of the specific toxicological cause of cardiac arrest is challenging, particularly in the out-of-hospital setting. The toxin may be unknown at the time treatment decisions are required, and some individuals may have been exposed to more than one toxin. These factors limit the feasibility of consistently selecting and administering toxin-specific treatments during resuscitation and make interpretation of the evidence challenging.
Although the certainty of evidence remained very low, the task forces noted that higher-dose hydroxocobalamin (>5g), in comparison to lower-dose hydroxocobalamin (≤5g), was associated with improved return of spontaneous circulation and survival in a small observational study of cyanide poisoning. Unfortunately, hydroxocobalamin treatment was not compared with no hydroxocobalamin treatment, thus precluding estimates of effectiveness. The certainty of evidence was insufficient to support a treatment recommendation, but this finding highlights the potential importance of identifying specific toxicological syndromes in which an administered antidote has a biologically plausible mechanism of benefit.
In one study E-CPR was also found to be associated with improved outcomes. The study included 10 patients with toxin-related cardiac arrest: (i) 3 cases who were treated with E-CPR and all survived; vs (2) 7 cases who were treated at a different hospital and not treated with E-CPR, and none survived. These data result in very low certainty evidence.
In the Australian EMS-registry based study, use of sodium bicarbonate was found to be associated with worse outcomes. However, the findings of this study were likely to be influenced by both selection bias and resuscitation time bias.7 Furthermore, use of sodium bicarbonate did not seem to be targeted at specific toxicological causes, potentially influencing the observed treatment effect. The task forces noted that this apparent signal of harm was inconsistent with a recent large randomised controlled trial in which 913 adults with in-hospital cardiac arrest of any etiology were randomized to receive sodium bicarbonate or placebo.8 For the 779 patients eligible for the primary analysis, use of sodium bicarbonate did not result in an increased rate of sustained return of spontaneous circulation (risk ratio 1.05, 95% CI 0.88-1.24, p = 0.62).
Existing guidance and implementation considerations
Toxicology organizations have developed guidelines for a range of toxins. The evidence supporting these guidelines varies from randomized controlled trials and observational studies to case studies, animal studies, and physiological principles. However, there is a paucity of evidence pertaining to patients experiencing cardiac arrest, and thus applicability of available evidence to patients with ongoing resuscitation is uncertain.
Some antidotes and other toxin-specific interventions may be complex to immediately access, prepare, and administer. The task forces were concerned that their use could detract from the delivery of high-quality standard resuscitation. In particular, the need to transport out-of-hospital patients to hospital with ongoing CPR for an unproven intervention may worsen outcomes. For an antidote to provide any possible benefit during cardiac arrest, it would need to be feasible to administer rapidly and have a sufficiently rapid onset of action (i.e. before irreversible neurological injury has been sustained), and be capable of reversing the relevant toxicological mechanism.
For EMS systems, even if an antidote was thought to be effective in cardiac arrest, limitations on physical storage and specific storage requirements, including refrigeration, may restrict the number of antidotes that can be carried. The available evidence does not support stocking particular antidotes specifically for use during cardiac arrest.
E-CPR
ILCOR has existing treatment recommendations for E-CPR across all causes of cardiac arrest in adults and children, with some addition condition-specific treatment recomendations.9-11 Some E-CPR programs may specifically identify toxicology-related cardiac arrest as eligible based on the belief that E-CPR may have benefit in this cohort. However, the comparative evidence identified by this review was extremely limited and at critical risk of bias, and thus unable to support a specific E-CPR treatment recommendation for toxicological causes of cardiac arrest.
Implications for practice
The available evidence does not support routine modification of standard resuscitation for non-opioid toxicological causes of cardiac arrest in children or adults.
The task forces considered it reasonable for providers to administer a toxin-specific antidote during cardiac arrest on a case-by-case basis. This decision should be informed by the likelihood of a specific toxicological cause, the biological plausibility and available evidence supporting the intervention, the availability of the antidote and speed of administration, and the need to avoid detracting from standard resuscitation delivery.
Knowledge Gaps
- Studies providing epidemiological data in both adults and children on the incidence of cardiac arrest with toxicological cause in- and out-of-hospital, including breakdown by toxin type.
- Randomised controlled trials comparing different treatment strategies for non-opioid toxicological causes of cardiac arrest in adults and children.
Evidence to Decision (EtD) Tables
ALS 3464 Evidence to Decision Table ETD November 2026
ALS 3464 Evidence Table November2026
References
1. Cole JB, Arens AM, Laes JR, Klein LR, Bangh SA, Olives TD. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am J Emerg Med. 2018;36:1817-1824. doi: https://dx.doi.org/10.1016/j.ajem.2018.02.004
2. Masson R, Colas V, Parienti JJ, Lehoux P, Massetti M, Charbonneau P, Saulnier F, Daubin C. A comparison of survival with and without extracorporeal life support treatment for severe poisoning due to drug intoxication. Resuscitation. 2012;83:1413-1417. doi: https://dx.doi.org/10.1016/j.resuscitation.2012.03.028
3. Fortin JL, Desmettre T, Manzon C, Judic-Peureux V, Peugeot-Mortier C, Giocanti JP, Hachelaf M, Grangeon M, Hostalek U, Crouzet J, et al. Cyanide poisoning and cardiac disorders: 161 cases. J Emerg Med. 2010;38:467-476. doi: https://dx.doi.org/10.1016/j.jemermed.2009.09.028
4. Alqahtani S, Nehme Z, Williams B, Bernard S, Smith K. Long-term trends in the epidemiology of out-of-hospital cardiac arrest precipitated by suspected drug overdose. Resuscitation. 2019;144:17-24. doi: https://dx.doi.org/10.1016/j.resuscitation.2019.08.036
5. Lind PC, Johannsen CM, Vammen L, Magnussen A, Andersen LW, Granfeldt A. Translation from animal studies of novel pharmacological therapies to clinical trials in cardiac arrest: A systematic review. Resuscitation. 2021;158:258-269. doi: https://doi.org/10.1016/j.resuscitation.2020.10.028
6. Andersen LW, Vammen L, Granfeldt A. Animal research in cardiac arrest. Resuscitation Plus. 2024;17:100511. doi: https://doi.org/10.1016/j.resplu.2023.100511
7. Andersen LW, Grossestreuer AV, Donnino MW. "Resuscitation time bias"-A unique challenge for observational cardiac arrest research. Resuscitation. 2018;125:79-82. doi: 10.1016/j.resuscitation.2018.02.006
8. Granfeldt A, Kirkegaard BL, Vallentin MF, Holmberg MJ, Stankovic N, Lind PC, Kjærgaard AG, Houe N, Vested M, Isbye DL, et al. Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2026;336:647-654. doi: 10.1001/jama.2026.10628
9. Holmberg MJ, Granfeldt A, Guerguerian AM, Sandroni C, Hsu CH, Gardner RM, Lind PC, Eggertsen MA, Johannsen CM, Andersen LW. Extracorporeal cardiopulmonary resuscitation for cardiac arrest: An updated systematic review. Resuscitation. 2023;182:109665. doi: 10.1016/j.resuscitation.2022.12.003
10. Drennan IR, Berg KM, Böttiger BW, Chia YW, Couper K, Crowley C, D’Arrigo S, Deakin CD, Fernando SM, Garg R, et al. Advanced Life Support: 2025 International Liaison Committee on Resuscitation Consensus on Science With Treatment Recommendations. Resuscitation. 2025;215. doi: 10.1016/j.resuscitation.2025.110806
11. Scholefield BR, Acworth J, Ng K-C, Tiwari LK, Raymond TT, Christoff A, Katzenschlager S, Escalante-Kanashiro R, Bansal A, Topjian A, et al. Pediatric Life Support: 2025 International Liaison Committee on Resuscitation Consensus on Science With Treatment Recommendations. Resuscitation. 2025;215. doi: 10.1016/j.resuscitation.2025.110813